Peru: COVID-19 vaccine agreements signed and under negotiation

Photo: ANDINA/Diffusion

16:42 | Lima, Mar. 11.

The Peruvian Government signed agreements with various pharmaceutical companies to acquire 48 million doses of coronavirus vaccines.

Signed contracts

As reported by the Foreign Affairs Ministry, Peru has signed agreements for the acquisition of vaccines with four laboratories:

Sinopharm: Agreement for 1 million doses that were delivered in a first batch of 300,000 last February 7, plus a second batch of 700,000 doses on February 13.

The

Pfizer: Agreement for 20 million doses, of which 100,000 have been brought to the country since March 3, 2021.

COVAX Facility: Agreement for 13.2 million doses. The COVAX Facility —a multilateral initiative that seeks to coordinate with vaccine manufacturers an equitable access to vaccines— has committed doses to immunize 6.6 million Peruvians.

There is also a commitment to deliver

AstraZeneca: Direct agreement for 14 million doses. The delivery of these vaccines will begin in the second half of 2021.

Negotiations in progress

Gamaleya: Negotiations for the acquisition of 20 million vaccine doses. It is being negotiated with the Russian Direct Investment Fund —a private company associated with the Gamaleya Institute, which produces the Sputnik V vaccine.

Johnson & Johnson:

Butantan Institute: Negotiations for 7 million doses. The Brazil-headquartered institute produces the Sinovac vaccine.

Moderna: Talks have begun with the U.S. laboratory offering 12 million doses.

(END) FHG/CVC/MVB

Published: 3/11/2021